Tourmaline Bio Valuation
| TRMLDelisted Stock | 47.98 0.00 0.00% |
At this time, the company appears to be overvalued. Tourmaline Bio has a current Real Value of USD35.03 per share. The regular price of the company is USD47.98. Our model measures the value of Tourmaline Bio from inspecting the company fundamentals such as Return On Equity of -0.3, shares outstanding of 25.69 M, and Price To Book of 4.75 X as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Tourmaline Bio's price fluctuation is very steady at this time. Calculation of the real value of Tourmaline Bio is based on 3 months time horizon. Increasing Tourmaline Bio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Tourmaline stock is determined by what a typical buyer is willing to pay for full or partial control of Tourmaline Bio. Since Tourmaline Bio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Tourmaline Stock. However, Tourmaline Bio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 47.98 | Real 35.03 | Hype 47.98 | Naive 51.34 |
The intrinsic value of Tourmaline Bio's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Tourmaline Bio's stock price.
Estimating the potential upside or downside of Tourmaline Bio helps investors to forecast how Tourmaline stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Tourmaline Bio more accurately as focusing exclusively on Tourmaline Bio's fundamentals will not take into account other important factors: Tourmaline Bio Total Value Analysis
Tourmaline Bio is at this time expected to have valuation of 993.63 M with market capitalization of 1.23 B, debt of 244 K, and cash on hands of . Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Tourmaline Bio fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
993.63 M | 1.23 B | 244 K |
Tourmaline Bio Asset Utilization
One of the ways to look at asset utilization of Tourmaline is to check how much profit was generated for every dollar of assets it reports. Tourmaline Bio has a negative utilization of assets of -0.21 %, losing USD0.002085 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Tourmaline Bio shows how discouraging it operates for each dollar spent on its assets.Tourmaline Bio Ownership Allocation
Tourmaline Bio shows a total of 25.69 Million outstanding shares. The majority of Tourmaline Bio outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Tourmaline Bio to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Tourmaline Bio. Please pay attention to any change in the institutional holdings of Tourmaline Bio as this could imply that something significant has changed or is about to change at the company. Also note that roughly nine hundred sixty thousand eight hundred ninety-one invesors are currently shorting Tourmaline Bio expressing very little confidence in its future performance.Tourmaline Bio Profitability Analysis
Net Loss for the year was (73.21 M) with profit before overhead, payroll, taxes, and interest of 0.About Tourmaline Bio Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Tourmaline Bio. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Tourmaline Bio based exclusively on its fundamental and basic technical indicators. By analyzing Tourmaline Bio's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Tourmaline Bio's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Tourmaline Bio. We calculate exposure to Tourmaline Bio's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Tourmaline Bio's related companies.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in Tourmaline Stock
If you are still planning to invest in Tourmaline Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Tourmaline Bio's history and understand the potential risks before investing.
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |